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reported AMD-CST3 association study, the evidence of a 
recessive effect on AMD risk is strengthened (OR = 1.89, 
P = 0.005). This effect closely resembles the AD-CST3 
recessive effect (OR = 1.73, P = 0.005) previously estab-
lished by meta-analysis. This resemblance is substanti-
ated by the high correlation between CST3 genotype and 
effect size across the two diseases (R2 = 0.978). A reces-
sive effect is in line with the known function of cystatin C, 
a potent enzyme inhibitor. Its potency means that, in het-
erozygous individuals, a single functional allele is suffi-
cient to maintain its inhibitory function; only homozygous 
individuals will lack this form of proteolytic regulation. 
Our findings support the hypothesis that recessively act-
ing variants account for some of the missing heritability 
of multifactorial diseases. Replacement therapy represents 
a translational opportunity for individuals homozygous for 
the mutant allele.
Introduction
Age-related macular degeneration (AMD) and Alzhei-
mer’s disease (AD) are progressive neurodegenerative dis-
eases exhibiting some common characteristics. A physical 
characteristic of both diseases is the presence of insoluble 
deposits at the site of pathogenesis. These pathological 
deposits—the amyloid plaques of AD and the drusen of 
AMD—demonstrate some compositional similarity, engen-
der a pro-inflammatory response and impair essential cel-
lular functions such as trafficking and secretion. These 
similarities indicate that common/similar cellular mecha-
nisms may contribute towards the pathogenesis of both 
diseases. Certain environmental risk factors, such as smok-
ing and obesity, are known to increase the risk of both dis-
eases, along with age which is the major risk factor for both 
Abstract Age-related macular degeneration (AMD) and 
Alzheimer’s disease (AD) are degenerative, multifactorial 
diseases involving age-related accumulation of extracel-
lular deposits linked to dysregulation of protein homeo-
stasis. Here, we strengthen the evidence that an nsSNP 
(p.Ala25Thr) in the cysteine proteinase inhibitor cystatin 
C gene CST3, previously confirmed by meta-analysis to be 
associated with AD, is associated with exudative AMD. To 
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variant that increases the risk of developing both AD and 
AMD. Furthermore, we demonstrate that the risk associ-
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study genotyping 350 exudative AMD Caucasian indi-
viduals. Bringing together our data with the previously 
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conditions. With respect to genetic risk factors the APOE 
gene is associated with both diseases but quite intriguingly 
has opposing directions of effect. Whereas the APOE ε4 
allele increases risk of developing AD, it decreases the risk 
of AMD (Baird et al. 2006; Logue et al. 2014; McKay et al. 
2011).
A polymorphism in the cystatin C gene (CST3) has also 
been implicated as a risk factor for both AD (Hua et al. 
2012) and AMD (Zurdel et al. 2002). The CST3 polymor-
phism associated with both diseases is a non-synonymous 
SNP (rs1064039) in the signal sequence (p.Ala25Thr due 
to a c.G73A substitution) which results in an alternate 
homologue referred to as variant B. Cystatin C is a potent 
inhibitor of cysteine proteases and multiple lines of evi-
dence (from molecular studies) support the hypothesis that 
wild-type cystatin C has a protective role against both these 
age-related diseases (Kaeser et al. 2007; Mi et al. 2007).
Meta-analysis of 8 association studies has confirmed 
that this SNP is associated with AD in Caucasians (Hua 
et al. 2012). Individuals homozygous for the variant were 
found to be at greatest risk (ORAA = 1.73, P = 0.005), 
while heterozygous individuals were not at significantly 
increased risk (ORAG = 1.06, P = 0.50), indicating that the 
risk allele acts recessively (Fig. S1). The genetic associa-
tion between CST3 and AMD has been less well studied, 
with only a single case–control study reported to date, in 
which an association between exudative AMD and the pol-
ymorphism was highlighted (Zurdel et al. 2002). Mirroring 
the AD association, Zurdel’s study found that it was those 
individuals homozygous with the variant that were found 
to be at the greatest risk of exudative AMD (ORAA = 3.03, 
P = 0.01), whereas heterozygotes were not at significant 
risk (ORAG = 1.06, P = 0.76). This identical recessive 
effect of CST3 on AMD and AD risk is intriguing. In the 
line of the above, the main aim of this study was to further 
investigate the AMD-CST3 association.
Methods
Association study subjects and ethics
A total of 350 Caucasian exudative AMD patients (126 
males and 224 females) were recruited (age range 65–96 
with mean 80.1 years). Written informed consent for all 
participants used in this study was obtained for research use 
and approved by the Leeds (East) Research Ethics Commit-
tee. The diagnosis of exudative AMD was provided by oph-
thalmologists based on baseline stereoscopic colour fun-
dus, fluorescein and indocyanine green angiogram images 
to identify lesion characteristics (McKibbin et al. 2012). 
Inclusion criteria for the study were that the patients were 
aged 65 years and over, with choroidal neovascularization 
(CNV) secondary to AMD and involving the centre of the 
fovea, and with the CNV occupying more than 50 % of 
total lesion area. Patients that had CNV secondary to path-
ological myopia, inflammatory disease, angioid streaks or 
trauma were excluded from this study. Tests for dementia 
were not performed on these cases.
Population controls were taken from the largest publicly 
available online database Exome Variant Server, NHLBI 
GO Exome Sequencing Project (ESP), Seattle, WA (http://
evs.gs.washington.edu/EVS/) (January 2014). This pro-
vided genotype information for 3781 Caucasians from the 
USA, which are assumed to contain undiagnosed AMD 
cases with a frequency equivalent to the Caucasian preva-
lence. We inferred that 2442 (64.5 %) of this sample are 
male, in that they have genotype information for the SRY 
gene.
Genotyping
Genomic DNA was extracted from peripheral blood leuco-
cytes by standard methods. Primers were designed using 
the online software Primer3 v.0.4.0 (http://frodo.wi.mit.
edu/). Polymerase chain reaction (PCR) generated a 1292-
bp product using forward primer CST3LRIIF 5′-CAG-
GAGTGGAGGAGGGAGATG-3′ and reverse primer 
CST3LRIIR 5′-CCAGATGAGGGGCTCTGTTTT-3′. This 
product contains three SNPs (rs5030707, rs73318135 and 
rs1064039) in strong linkage disequilibrium, such that 
the genetic variation can be explained by two haplotypes, 
known as variant A and variant B. Two of the SNPs are 
located in the 5′ untranslated region and the third is located 
in exon 1 (leading to the missense p.A25T). Briefly, the 
PCR consisted of 40 ng of genomic DNA, 2pM of each 
forward and reverse primer, 1M Betaine and HotShot Mas-
termix (Clent Life Sciences, Stourbridge, UK). An initial 
denaturation step of 95 °C for 12 min was followed by 
40 cycles of 94 °C for 30 s, 60 °C for 30 s and 72 °C for 
60 s. A final extension of 75 °C for 5 min completed the 
reaction. PCR products were electrophoresed on a 1.5 % 
agarose gel stained with ethidium bromide after which the 
gel was visualized using the ultraviolet light filter on the 
ChemiDoc Imaging system (BioRad).
Sanger sequencing
PCR products were digested with ExoSAP-IT (Affy-
metrix USB, Santa Carla, USA) and sequencing reac-
tions were carried out using Big Dye Terminator Cycle 
Sequencing V3.1 Ready Reaction Kit (Applied Biosys-
tems, Warrington, UK). To determine the sequence at SNPs 
rs5030707, rs73318135 and rs1064039 nested reverse 
CST3LRR primer 5′-GGCTCCTGGAAGCTGATCT-
TAG-3′ was used. To confirm the sequence a second nested 
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reverse primer CST3BIIR 5′-TTGCTGGCTTTGTT-
GTACTCGC-3′ was used. The sequence data obtained 
from both primers was compared to see if they matched 
and together these data were used to determine the haplo-
types. The sequencing reactions were run on an ABI3130xl 
Genetic Analyser and the data analysed for respective SNPs 
using Sequence Analysis 5.2 software (Applied Biosys-
tems). Representative chromatograms of each of the three 
genotypes are presented in Supplementary Fig. S2.
Statistical analyses
The odds ratios and 95 % confidence intervals are log 
transformed to determine the mean and variance corre-
sponding to the asymptotically normally distributed effect 
sizes (denoted as β). By calculating these parameters for 
both the heterozygote (βAG) and homozygote (βAA), we are 
able to make inferences about the genetic model of inherit-
ance. Explicitly we test for the recessive model by testing 
the null hypothesis H0: d = βAA − βAG = 0, Ha: d > 0 as 
previously described (Bagos 2008).
To summarize the level of homogeneity between AMD 
and AD effect sizes across both genotypes, we calculate the 
coefficient of determination from the four estimated ORs. 
We also test the null hypothesis that CST3 has no effect on 
both diseases, or equivalently that the mean effect size is 
zero (H0 : βAMD = βAD = β = 0). Here, the weighted 
mean and variance of the mean (using inverse-variance 
weighting) are used to determine the appropriate z-score 
and corresponding P value.
To test whether there is a significant difference in the 
distribution of three genotypes between AMD cases and 
controls we performed a two-sided Fisher’s exact test, 
conducted in R (R Core Team 2014). Meta-analysis was 
performed using Cochrane Review Manager with Mantel–
Haenszel estimation (The Cochrane Collaboration 2012). 
Random effects meta-regression was performed in R using 
the ‘glmer’ function from the lme4 package.
Power calculations for AMD association studies 
of CST3 variant
To determine the power of the association study of Zurdel 
et al. (2002) a single iteration randomly allocates a geno-
type (“AA”, “AG” or “GG”) to 517 simulated controls 
and 167 simulated cases, the sample sizes of this study. 
The probabilities used to allocate are calculated from the 
alternative hypothesis effect sizes, which is taken to be 
that reported by the AD meta-analysis (ORAG = 1.06, 
ORAA = 1.73). From this simulated case–control dataset 
we perform a two-tailed z test (on the logORAA scale) at 
α = 0.05. After 10,000 iterations the number that success-
fully detected an association is used to estimate power. This 
is repeated for our study by changing the sample sizes of 
cases and controls accordingly. For the two-study meta-
analysis, power calculation requires simulating the two 
case–control data sets for each iteration and performing the 
z test based on the weighted normal distribution (equivalent 
to a fixed-effect meta-analysis).
Results
Recessive effect of CST3 variant previously observed 
in both AD and AMD
Association between the CST3 SNP (rs1064039) and AD 
has been established by meta-analysis (Hua et al. 2012). 
The exact same SNP has also been identified to be associ-
ated with AMD (Zurdel et al. 2002). Using the data from 
both these studies, we calculate the effect sizes separately 
for heterozygotes “AG” and homozygotes “AA”, against 
the baseline “GG” (Fig. 1, Fig. S1). We observe that for 
both diseases, risk is significantly increased only for 
the homozygotes (AD: ORAA = 1.73, P = 0.005; AMD: 
ORAA = 3.03, P = 0.01), whereas the heterozygote risk 
is non-significant for both diseases (AD: ORAG = 1.06, 
P = 0.50; AMD: ORAG = 1.06, P = 0.76). Thus a reces-
sive model of inheritance best explains the association with 
CST3 for both diseases. To support this recessive model we 
confirm that homozygote effect size is significantly greater 
than the heterozygote effect size in both AD (P = 0.010) 
and in AMD (P = 0.013). Put together the risk “A” allele is 
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Fig. 1  Odds ratios for CST3 genotypes at rs1064039 estimated for 
AD by meta-analysis and for AMD by a single association study. ORs 
are measured relative to the “GG” genotype, by definition this base-
line genotype has an OR of 1. Error bars represent 95 % CIs
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recessive for both diseases; only individuals with two cop-
ies of it are at a significantly higher risk of developing AD 
and AMD.
To quantify the similarity between the ORAA for AD 
and AMD, we also calculated how probable it would be to 
simultaneously observe both these ORs by chance given the 
null hypothesis that CST3 has no effect on both diseases. 
We find that such a set of observations is very unlikely to 
happen by chance (P = 5.0 × 10−4). To further quantify the 
similarity between the CST3 genotype data of the two dis-
eases, we calculate the coefficient of determination of the 
four variables (Fig. 1) and find R2 = 0.673.
Power of existing association studies to detect CST3 
recessive effect is estimated to be low
To estimate the power of an association study an estimate 
of the effect size of the alternative hypothesis is required. 
Because both molecular and epidemiological evidence sup-
port homogeneity between AMD and AD with respect to 
CST3, we use its AD effect size estimated by meta-analysis 
(ORAA = 1.73) as a reasonable estimate for its AMD effect 
size. Using this assumption and a z test for recessive effect 
we calculate the power of Zurdel’s study (167 cases, 517 
controls) to be 24.6 %. Thus for every four studies of such 
size, only one would detect the association.
We also estimated the power of a GWAS to detect an 
association with a variant with this recessive effect size. 
Using the sample sizes, test and significance level of an 
existing AD GWAS (Harold et al. 2009), we estimated 
the power to be 14.8 %. One reason for this low power is 
that the standard GWAS uses a test based on an additive 
model. This test performs poorly when the true causal vari-
ant is recessive (Lettre et al. 2007). We calculated that the 
per-allele (or additive model) odds ratio, ORA, would be 
1.15 given a true recessive effect of ORAA = 1.73 (given 
the allele frequency of rs1064039 and HWE in controls). 
From further study of this relationship we found that for 
a given recessive effect size, ORNN, the perceived per-
allele ORN is linearly related to the allele frequency of the 
SNP (Fig. 2). Thus even a variant with a large recessive 
effect (ORNN = 3) and moderate allele frequency (10 %) 
can appear to have a weak effect from its per-allele OR 
(ORN = 1.2).
Novel AMD-CST3 case–control study consistent 
with recessive effect
On observing these findings we sought to replicate the find-
ing of Zurdel et al. in investigating the association between 
CST3 and AMD. The CST3 SNP (rs1064039) was geno-
typed in Caucasian AMD patients from England (n = 350). 
We tested this AMD data against the Exome Sequencing 
Project control data as it was the largest publically avail-
able set of population controls (n = 3781). In this control 
sample the frequency of the variant allele “A” is 17.5 % 
and the proportion with the “AA” genotype is 3.0 %. Thus 
the data are in Hardy–Weinberg equilibrium (P = 0.76) and 
also fall within the allele frequency range reported from the 
Caucasian studies in the AD meta-analysis, which ranged 
from 17.1 to 22.8 %.
Case–control analysis of these results exhibits a highly 
similar pattern of genotype risks to those observed by Zur-
del (Table 1), but is not significant at an alpha level of 0.05 
(two-sided Fisher’s exact test: P = 0.25). Although not 
significant, it is the “AA” homozygotes that are at greatest 
risk (ORAA = 1.56, P = 0.11) compared to the heterozy-
gotes (ORAG = 1.07, P = 0.58), with “GG” homozygotes 
as baseline. Thus our data are consistent with the reces-
sive effect observed previously in both AMD and AD, but 
are not powerful enough to reach significance by itself. 
Further indication of an effect was obtained by perform-
ing the analysis only on AMD cases aged above 80 years 
(ORAA = 2.05, P = 0.03, n = 188). However, all further 
analyses in this study are performed on the total AMD 
dataset (i.e. ≥65 years, n = 350).
We calculate the power of our study alone to be 53.7 %, 
meaning that around half of studies this size would fail 
to detect the association given the effect size reported for 
AD. The relatively low powers presented so far are likely 
due to the frequency of the homozygote risk genotype. 
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Fig. 2  The per-allele odds ratio (ORN) decreases linearly with 
decreasing allele frequency (fN) when the true model is recessive; the 
elevated risk of homozygotes is kept constant (ORNN specified) and 
heterozygotes are at baseline risk (ORNX = 1). This relationship can 
be expressed as: ORN = fN(ORNN − 1) + 1. The single point repre-
sents CST3 rs1064039 with respect to AD
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For instance within our sample of 350 AMD cases, only 
16 (4.6 %) are “AA” homozygotes (Table 1). To achieve a 
power of 80 % (assuming the effect size is equivalent to 
AD, ORAA = 1.73), we calculate it would require a sample 
of 735 AMD cases, whilst maintaining the control sample 
size of 3781.
Combining AMD-CST3 studies strengthens evidence 
of a recessive effect
We proceeded to perform a preliminary meta-analysis to 
bring together the results of the two CST3-AMD associa-
tion studies. First we apply a fixed-effects meta-analysis 
to the “AA” genotypes versus the baseline “GG” and 
determine a significant effect (ORAA = 1.89, P = 0.005) 
(Fig. 3a). We estimate the power of this two-study meta-
analysis to be 67.7 %, greater than either of its constitu-
ent association studies as expected. Thus, taken together, 
the two association studies indicate a significant overall 
recessive effect of CST3 genotype on AMD risk. We also 
performed the meta-analysis using a random effects analy-
sis and with this more conservative method the significant 
recessive effect is maintained (ORAA = 2.00, P = 0.032). 
We also repeated the random effects meta-analysis using a 
meta-regression approach (Turner et al. 2000), and found 
the results matched well (ORAA = 2.17, P = 0.026) with 
the conventional random effects meta-analysis.
We calculated how probable it would be to simultane-
ously observe both ORAA under the null hypothesis of 
CST3 having no effect on either disease. We found that this 
updated set of observations was even more unlikely to hap-
pen by chance (P = 7.8 × 10−5) than previously calculated. 
We then applied an AMD meta-analysis to the “AG” het-
erozygotes versus the baseline “GG” genotype (Fig. 3b), 
and determined a non-significant effect (ORAT = 1.06, 
P = 0.55). Finally, we compared the AMD and AD effect 
sizes estimated from their respective meta-analysis along-
side one another and observed a striking similarity (Fig. 4). 
Using the updated AMD effect sizes we found that the 
coefficient of determination now becomes very high 
(R2 = 0.978), supporting the hypothesis that homogene-
ity exists between AMD and AD risk with respect to CST3 
genotype.
Discussion
We bring together AD and AMD case–control data and 
observe that not only is CST3 associated with both diseases 
but there is a striking similarity in the underlying model 
Table 1  Distribution of CST3 rs1064039 genotypes in exudative 
AMD case and control samples from Caucasian population
a Odds ratio were calculated separately against G/G baseline geno-
type
Genotypes Frequencies (%) ORa (95 % CI) P value
Case Control
G/G (baseline) 230 (65.7) 2574 (68.1) 1 –
G/A 104 (29.7) 1092 (28.9) 1.07 (0.84–1.36) 0.58
A/A 16 (4.6) 115 (3.0) 1.56 (0.91–2.67) 0.11
A
B
Fig. 3  Forest plots for the meta-analysis of CST3 rs1064039 with 
respect to exudative AMD in the Caucasian population using a fixed 
effects model. Size of the squares represents the weight of the study 
and horizontal bars represent 95 % CI of the OR. Applied to a “AA” 
genotype versus “GG” genotype and b “AG” genotype versus “GG” 
genotype
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of inheritance, namely a recessive genetic model. We first 
noticed this similarity by bringing together an AD-CST3 
meta-analysis and the only reported association study 
between CST3 and AMD. Under the null hypothesis that 
both diseases are not affected by CST3 genotype the com-
bined observed data are very unlikely to occur by chance 
(P = 5.0 × 10−4). However, we estimated the power of this 
AMD association analysis to be fairly low (24.6 %), assum-
ing the AMD effect size is equivalent to AD. On repeating 
the AMD association study, again the same recessive trend 
was observed with only the homozygote variants at ele-
vated risk. Taken together a meta-analysis of the two AMD-
CST3 studies finds a significant association (P = 0.005) 
with an increased estimated power of 67.7 %. The reces-
sive trend is strikingly similar between the two diseases 
(Fig. 4), with only the “AA” homozygotes at a significantly 
elevated risk of developing both AMD and AD, whereas the 
heterozygotes are non-significant and effectively equivalent 
in both diseases. The combined dataset of all AMD and 
AD studies is now even more unlikely to occur by chance 
(P = 7.8 × 10−5) given the null hypothesis that CST3 has 
no effect on both diseases.
Although an estimated power of 67.7 % was achieved 
through the two-study meta-analysis, more replication 
association studies are necessary to validate a role of CST3 
in AMD pathogenesis. It is also important to note that both 
of these AMD association studies were performed with 
Caucasian samples only. With AD the association with 
CST3 was only found in Caucasian samples, while in Asian 
samples no significant AD-CST3 association was detected 
(Hua et al. 2012). Whether this ethnic disparity also trans-
lates across to AMD remains to be determined. A further 
aspect of the AMD-CST3 association that remains to be 
unravelled is whether there is any epistasis between CST3 
and other known AMD genetic risk factors such as CFH, 
ARMS2 and APOE.
We are aware that GWASs of AMD have failed to report 
an association at CST3 (Arakawa et al. 2011; Chen et al. 
2010; Cipriani et al. 2012; Fritsche et al. 2013; Neale 
et al. 2010; Yu et al. 2011). However, the fact that it has 
not reached genome-wide significance does not preclude it 
as a risk variant. This is demonstrated by the fact that the 
AD-CST3 association, validated by candidate gene meta-
analysis (Hua et al. 2012), has also not been reported in 
any GWAS for AD (Harold et al. 2009; Hollingworth et al. 
2011; Lambert et al. 2009; Naj et al. 2011; Seshadri et al. 
2010), nor a GWAS meta-analysis (Lambert et al. 2013). 
It follows that all the AD GWASs failed to detect the asso-
ciation, not because there is no association, but because the 
GWAS must be underpowered to detect it.
One explanation for this is that an association can 
be missed due to a recessive effect. A limitation of most 
GWASs is that they utilize a one-degree of freedom test 
optimal for detecting an additive disease model, but which 
performs poorly if the actual disease model is recessive 
(Lettre et al. 2007). We find that the size of this variant’s 
recessive effect (ORAA = 1.73) is concealed when only con-
sidering its additive or per-allele effect size (ORA = 1.15). 
Herein, we propose that this explanation also serves as a 
hypothesis to account for some of the current “missing her-
itability” for common diseases. For AMD only 15–65 % 
of total heritability is explained by the 19 loci detected so 
far (Fritsche et al. 2013). A number of hypotheses have 
sought to predict the nature of the undetected genetic 
variants that account for this considerable missing herit-
ability. One hypothesis proposes that it is due to common 
variants with weak effect, also known as the infinitesimal 
model (Gibson 2011) and has a growing body of support-
ing evidence (Hunt et al. 2013). We propose that a subset 
of these common variants with weak effect are likely to be 
common variants with recessive effect (CVRE). We con-
sider this distinction important as it gives further promise 
for detecting additional associated variants using currently 
employed sample sizes. Although a common recessive vari-
ant may be considered weak using an additive model, its 
recessive effect (ORNN) can be much stronger (Fig. 2) and 
therefore could be detected using an appropriately designed 
test. We predict that it will be very informative to analyse 
existing GWAS datasets to test specifically for recessive 
effects. We consider the CVRE hypothesis is consistent 
with the knowledge that there are many simple genetic dis-
eases known to be recessive, and that recessive variants are 
now beginning to be found in complex diseases (Yang et al. 
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Fig. 4  Odds ratios for CST3 genotypes at rs1064039 estimated for 
AD and AMD meta-analyses. Note that the odds ratios are measured 
relative to the “GG” genotype, by definition this baseline genotype 
has an odds ratio of 1. Error bars represent 95 % CIs
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2012). Indeed other candidate gene studies of AMD have 
discovered associated variants with recessive effect (Jun 
et al. 2011), which were not detected by the AMD GWASs. 
The CVRE hypothesis is also consistent with the fact that a 
recessive variant is more likely to rise to a common allele 
frequency than a dominant or additive variant because it is 
under less selective pressure (Curtis 2013).
We present evidence that CST3 is a shared genetic 
risk factor for both AMD and AD. It was anticipated that 
variants linked to AMD may contribute to other prevalent 
age-related diseases involving chronic, local inflamma-
tory processes (Hageman 2012). It has also been docu-
mented that both AD plaques and AMD drusen involve 
amyloid-β peptides and the complex enzymatic systems 
necessary to generate them (Zhao et al. 2014). A well-
known gene implicated in both diseases is APOE. Inter-
estingly however this actually exhibits antagonistic 
pleiotropy, whereas the ε4 allele increases an individual’s 
AD risk it decreases AMD risk. Due to this and other 
unshared risk factors, we do not expect the shared asso-
ciation of CST3 to be sufficient to cause comorbidity 
between AD and AMD. Indeed a recent study did not find 
a significant shared incidence between the two diseases 
(Keenan et al. 2014). However, this is not to say this is 
a research opportunity not worth exploring; understand-
ing more about the functional mechanism of cystatin C 
and its associated cellular pathways may provide insights 
into both diseases, and identify further molecular targets 
for treatment and prevention. Furthermore, the recessive 
nature may be favourable with respect to therapeutics; 
a number of autosomal recessive diseases have already 
been successfully treated using replacement therapy. 
Replacing the dysfunctional or deficient gene with a 
functional copy has been achieved by administering the 
Fig. 5  Pairwise linkage disequilibrium map of CST3 SNPs (maf 
>0.05) from a Caucasian sample (n = 503, from Phase 3 of the 1000 
Genomes Project). Solid black squares represent pairs of SNPs in 
high LD (R2 > 0.9) as depicted by Haploview. Missense SNP high-
lighted in red, the two other SNPs in the PCR product highlighted in 
blue, and the SNP associated with plasma level of cystatin C high-
lighted in green (colour figure online)
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functional protein (Escobar 2013) and more recently by 
using gene therapy (Gaudet et al. 2013).
Further support for the CST3 nsSNP having a functional 
role comes from a recent GWAS that detected an associ-
ation (P = 7.82 × 10−16) between an SNP 1.3 kb down-
stream of CST3 (rs6048952) and plasma levels of cystatin 
C (Akerblom et al. 2014). We found the variant that cor-
responds to decreased plasma cystatin C is on the same 
haplotype as the AMD/AD risk allele rs1064039-A (pair-
wise LD: R2 = 0.92, D′ = 0.99) (Fig. 5). This observation 
presents a mechanistic link between genotype and disease 
phenotype and it also lends further support to the idea that 
cystatin C replacement therapy may be a fruitful therapeu-
tic avenue. We maintain that the rs1064039 polymorphism 
is the driver of the reduced secretion because transfection 
of RPE cells with a construct encoding a different amino 
acid (serine) at that position leads to an intermediate level 
of secretion, between the wild type (alanine) and variant 
B (threonine) levels (Ratnayaka et al. 2007). Decreased 
secretion of cystatin C has also been observed in fibroblasts 
taken from AD donors homozygous for variant B when 
compared with fibroblasts from AD donors heterozygous or 
wild-type homozygous (Benussi et al. 2003).
In conclusion, we present evidence that strengthens the 
hypothesis that CST3 is implicated in AMD pathogenesis. 
In particular, only individuals homozygous for the variant 
allele are at increased risk. Intriguingly the same recessive 
effect is observed at the same SNP with AD risk. This find-
ing corresponds with previous evidence from both AD and 
AMD in vitro models. Observing a recessive effect implies 
that a single wild-type allele is able to compensate for the 
mutant allele. This may be due to cystatin C being a potent 
inhibitor of cysteine proteases (inhibitory constant ki for 
cathepsin B is 0.25 nM) (Barrett et al. 1984). Therefore, 
gene expression from a single wild-type copy is expected 
to maintain proteolytic homeostasis, whereas absence of 
both wild-type copies is likely to lead to proteolytic dys-
regulation. It is interesting to note that proteolytic dys-
regulation has been implicated in the pathogenesis of both 
AMD and AD (Kaarniranta et al. 2011). Specifically inhibi-
tion of cathepsin B has been shown to play an important 
role in improving memory function and reducing levels of 
β-amyloid in transgenic AD mice (Hook et al. 2008). It is 
also interesting that another protease inhibitor, TIMP3, has 
recently been linked with susceptibility to AMD (Ardeljan 
et al. 2013; Fritsche et al. 2013). Further research will be 
required to fully elucidate the roles of protease inhibitors 
with respect to AMD pathogenesis.
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